These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6084708)

  • 1. Antitumor agent poly (amino acid) conjugates as a drug carrier in cancer chemotherapy.
    Morimoto Y; Sugibayashi K; Sugihara S; Hosoya K; Nozaki S; Ogawa Y
    J Pharmacobiodyn; 1984 Sep; 7(9):688-98. PubMed ID: 6084708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of sarcolysin with histones of Yoshida's sarcoma of strains sensitive and resistant to alkylating agents.
    Panosyan GA
    Bull Exp Biol Med; 1974 Jun; 76(12):1442-4. PubMed ID: 4421340
    [No Abstract]   [Full Text] [Related]  

  • 3. Biomedical applications of chemically and microbiologically synthesized poly(glutamic acid) and poly(lysine).
    Shih IL; Van YT; Shen MH
    Mini Rev Med Chem; 2004 Feb; 4(2):179-88. PubMed ID: 14965290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of melphalan on a sensitive and a resistant Yoshida ascites tumour.
    Cooper EH; Tipping NE
    Acta Genet Med Gemellol (Roma); 1968 Jan; 17(1):40-50. PubMed ID: 5659735
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanism of protection afforded by polyaspartic acid against gentamicin-induced phospholipidosis. II. Comparative in vitro and in vivo studies with poly-L-aspartic, poly-L-glutamic and poly-D-glutamic acids.
    Kishore BK; Lambricht P; Laurent G; Maldague P; Wagner R; Tulkens PM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):875-85. PubMed ID: 1700819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potentiating action of cobra venom cytotoxin on the antitumour effects of an alkylating agent (melphalan).
    Braganca BM; Hospattankar AV
    Eur J Cancer (1965); 1978 Jun; 14(6):707-12. PubMed ID: 658095
    [No Abstract]   [Full Text] [Related]  

  • 7. The selectivity of action of alkylating agents and drug resistance. I. Biochemical changes occurring in sensitive and resistant strains of the Yoshida ascites sarcoma following chemotherapy.
    Harrap KR; Hill BT
    Br J Cancer; 1969 Mar; 23(1):210-26. PubMed ID: 5768437
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effects of poly-L-lysine, poly-L-glycine and poly-L-glutamic acid on ANS fluorescence and electrokinetic potential of splenic lymphocytes in the mouse].
    Vaillier J; Vaillier D; Lematre J
    Rev Can Biol Exp; 1983 Jul; 42(2):151-62. PubMed ID: 6196811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The selectivity of action of alkylating agents and drug resistance. 3. The uptake and degradation of alkylating drugs by Yoshida ascites sarcoma cells in vitro.
    Harrap KR; Hill BT
    Biochem Pharmacol; 1970 Jan; 19(1):209-17. PubMed ID: 5507636
    [No Abstract]   [Full Text] [Related]  

  • 10. Evidence for carrier-mediated transport of melphalan by L5178Y lymphoblasts in vitro.
    Goldenberg GJ; Lee M; Lam HY; Begleiter A
    Cancer Res; 1977 Mar; 37(3):755-60. PubMed ID: 837375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Water-soluble porphyrin-PAMAM-conjugates of melphalan and their anticancer activity.
    Ramírez-Arroniz JC; Martínez Klimova E; Pedro-Hernández LD; Organista-Mateos U; Cortez-Maya S; Ramírez-Ápan T; Nieto-Camacho A; Calderón-Pardo J; Martínez-García M
    Drug Dev Ind Pharm; 2018 Aug; 44(8):1342-1349. PubMed ID: 29521131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Controlled release of adriamycin from silicone elastomer and its antitumor effects on Yoshida Sarcoma].
    Yanagiya K
    Kokubyo Gakkai Zasshi; 1986 Jun; 53(2):386-405. PubMed ID: 3464661
    [No Abstract]   [Full Text] [Related]  

  • 14. Modulation of the toxicity and antitumour activity of alkylating drugs by steroids.
    Shepherd R; Harrap KR
    Br J Cancer; 1982 Mar; 45(3):413-20. PubMed ID: 7073935
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An anti-alpha-fetoprotein antibody-daunorubicin conjugate with a novel poly-L-glutamic acid derivative as intermediate drug carrier.
    Tsukada Y; Kato Y; Umemoto N; Takeda Y; Hara T; Hirai H
    J Natl Cancer Inst; 1984 Sep; 73(3):721-9. PubMed ID: 6206272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regiospecific gamma-conjugation of methotrexate to poly(L-lysine). Chemical and biological studies.
    Rosowsky A; Forsch RA; Galivan J; Susten SS; Freisheim JH
    Mol Pharmacol; 1985 Jan; 27(1):141-7. PubMed ID: 3965926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid-conferred resistance to melphalan. I. Structure-activity relationship in cultured murine L1210 leukemia cells.
    Vistica DT; Toal JN; Rabinovitz M
    Cancer Treat Rep; 1976 Sep; 60(9):1363-7. PubMed ID: 1016969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on the mechanism of resistance to alkylating agents of three ascites tumours in the rat.
    Poynter RW
    Biochem Pharmacol; 1970 Apr; 19(4):1387-97. PubMed ID: 4327763
    [No Abstract]   [Full Text] [Related]  

  • 19. Differently charged polypeptides in the prevention of post-surgical peritoneal adhesions.
    Nehéz L; Tingstedt B; Axelsson J; Andersson R
    Scand J Gastroenterol; 2007 Apr; 42(4):519-23. PubMed ID: 17454864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conjugation of methotrexate to poly (L-lysine) as a potential way to overcome drug resistance.
    Ryser HJ; Shen WC
    Cancer; 1980 Mar; 45(5 Suppl):1207-11. PubMed ID: 7357512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.